Lucid Diagnostics to Host Business Update Call on November 12

Lucid Diagnostics Inc. will conduct a business update conference call and webcast on November 12, 2025, at 8:30 AM Eastern Time. The event will feature key insights on the company’s operations and growth strategies.

During the call, Lishan Aklog, M.D., who serves as the Chairman and Chief Executive Officer of Lucid, will deliver an overview of the company’s business performance. Additionally, Dennis McGrath, the Chief Financial Officer, will share the financial results for the third quarter of 2025.

The webcast will be accessible via the investor relations section of Lucid Diagnostics’ website at luciddx.com. Participants who prefer to join the conference call by phone can do so by calling 1-800-836-8184 for U.S. listeners or 1-646-357-8785 for international participants. Callers must mention “Lucid Diagnostics Business Update” to access the conference.

After the call concludes, a replay will be available for 30 days on the investor relations section of the website, allowing stakeholders to review the information presented.

Focus on Cancer Prevention

Lucid Diagnostics, a subsidiary of PAVmed Inc., specializes in cancer prevention through innovative medical diagnostics. The company targets patients suffering from gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at heightened risk for esophageal precancer and cancer.

The company’s flagship products include the EsoGuard® Esophageal DNA Test and the EsoCheck® Esophageal Cell Collection Device. These tools are designed for early detection of esophageal precancer through a brief, noninvasive office procedure, representing the first commercially available solutions aimed at reducing cancer mortality rates in at-risk populations.

For more information about Lucid Diagnostics and its efforts in cancer prevention, visit www.luciddx.com. To learn more about its parent company, PAVmed, go to www.pavmed.com.

This upcoming business update presents a significant opportunity for investors and stakeholders to understand the company’s trajectory and financial health, reinforcing Lucid’s commitment to advancing cancer prevention strategies.